Delivery Order SPE2DB22D1106-SPE2DB25FFCD3
- Not listed
- The Defense Logistics Agency awarded a $7,794.93 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count unit). The contract utilizes firm fixed-price pricing with an ultimate completion date of July 29, 2025, and represents a non-competitive, non-set-aside award. This delivery order is executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $1...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count) with a ceiling value of $1,368.56. This is a firm fixed price delivery order with an ultimate completion date of August 26, 2025, and represents a non-competitive set-aside award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Myrbetriq ER 25 mg tablets (90-count units) with a ceiling value of $33,370.13. This firm fixed-price delivery order, which is not set-aside and competitively awarded, is performed at the contractor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 19, 2025. The contract represents a continuation of AmerisourceBergen's...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 15, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count package) valued at $5,513.58. This firm fixed-price delivery order, with an ultimate completion date of July 16, 2025, represents a non-competitive award under a larger contract vehicle. The product will be delivered to the Place of Performance in Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count) with a ceiling value of $4,216.17. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The order is set for completion by August 27, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Myrbetriq ER 25 mg tablets (90-count units) with a contract ceiling value of $7,553.60. This is a firm fixed-price delivery order with no set-aside designation, utilizing open and competitive procurement procedures. The contract is set to complete by August 1, 2025, and represents a direct fulfillment of pharmaceutical supply needs through AmerisourceBergen's existing...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count units) with a ceiling value of $43,308.34. This firm fixed-price delivery order, without set-aside designation, represents a competitive award under an open solicitation process. The contract is scheduled for completion by September 22, 2025, and will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Myrbetriq ER 25 mg tablets (90-count units) valued at $10,076.28. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and is scheduled for completion by August 13, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfilled this order through its corporate office...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count) with a ceiling value of $30,440.85. This firm fixed-price delivery order, which is a child contract under a larger vehicle, reflects no set-aside designation and represents a competitively awarded transaction. The order will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania, with an...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count units) with a ceiling value of $8,029.97. This is a firm fixed-price delivery order with no set-aside designation, issued under a competitive procurement process. The order is set for ultimate completion on August 13, 2025, with performance fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility, which serves as the...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FFCD3Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count units) with a ceiling value of $43,359.95. This firm fixed-price delivery order, which is scheduled for completion by August 8, 2025, represents a non-competitive set-aside award and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026 that enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to military healthcare systems worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement, particularly supporting Defense Health Agency and military healthcare programs. The company maintains an extensive portfolio of federal contract awards with the DLA covering diverse pharmaceutical products across multiple therapeutic domains. This delivery order for Myrbetriq ER—a medication used to treat overactive bladder—exemplifies the company's role in supplying both brand-name and generic medications to support the military's medical supply chain requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $43.4k | 8/7/25 |